In this podcast, Brian Wojciechowski, MD, Breastcancer.org medical adviser, discusses some of the research that was published in July 2014.
In this podcast, Brian Wojciechowski, M.D., Breastcancer.org medical adviser, discusses some of the research that was published in July 2014. Listen to the podcast to hear Dr. Wojciechowski talk about:
Running time: 20:50
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes vs Chemo in Urothelial Cancer
April 20th 2024Patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin plus pembrolizumab experienced a reduction in the risk for disease progression or death vs chemotherapy.
Dual Checkpoint Inhibition Increases Response Rates, Adverse Effects in Melanoma
April 19th 2024Patients with high-risk resectable melanoma treated with ipilimumab plus nivolumab had increased response rates compared with anti-PD1 monotherapy, though it was also associated with increased immune-related adverse effects.